Boris Pasche: Karmanos Cancer Institute Leads Innovation in Cancer and Hematologic Disease Treatment
Boris Pasche, President and CEO at Karmanos Cancer Institute, shared a post on LinkedIn:
“Karmanos Cancer Institute continues to lead in medical science by providing patients with exceptional treatment opportunities for cancer and hematologic diseases.
As a pioneer in Theranostics, phase I trials, medical devices, and now gene therapy for hemophilia, Karmanos exemplifies its mission to transform care, research, and education in these fields through courage, commitment, and compassion.
With 17 locations throughout Michigan, Karmanos also offers second opinions, often introducing patients to novel therapies they may not have previously considered.
For more information on their groundbreaking work, check out this article: Karmanos is first independent cancer center to treat hemophilia B with new gene therapy.”
Stay updated with Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention